Jasbir Seehra, Ph.D., is a distinguished biopharmaceutical executive and scientist who currently serves as the Chief Executive Officer and Director at Keros Therapeutics Inc. Dr. Seehra has a robust background in drug discovery and development, with a career spanning over three decades. He earned his Ph.D. in biochemistry from the University of London and has held several leadership positions in the biopharmaceutical industry, including key roles at Shire and Acceleron Pharma. At Shire, he was instrumental in advancing the company's hematology portfolio, while at Acceleron, he contributed significantly to the development of novel therapeutics targeting musculoskeletal and hematologic disorders. In his role at Keros Therapeutics, Dr. Seehra leads the company's efforts to develop and commercialize transformative treatments for hematological and musculoskeletal disorders. Under his leadership, Keros has made significant strides in advancing its pipeline, which includes promising candidates such as KER-050 and KER-047. These therapies aim to address unmet medical needs in conditions like myelodysplastic syndromes and pulmonary arterial hypertension. Dr. Seehra's strategic vision and scientific expertise have been pivotal in guiding Keros through its growth phases, including successful fundraising efforts and clinical trial advancements. Dr. Seehra's contributions to the field extend beyond his executive roles. He is an author of numerous scientific publications and holds several patents, reflecting his innovative approach to drug development. His dedication to improving patient outcomes and his ability to foster a collaborative research environment have earned him recognition within the industry. As CEO of Keros Therapeutics, Dr. Seehra continues to drive the company's mission to transform the lives of patients suffering from debilitating diseases, solidifying his reputation as a leader in biopharmaceutical innovation.